Physician profile
David B Holt
NPI 1508805888
$6,551.51
in general payments reported to CMS, 2019-2025
39 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $751 · 2021: $1,006 · 2022: $762 · 2023: $1,060 · 2024: $1,161 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $506.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $491.82 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $489.75 | 2019-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Astellas Pharma US INC | $476.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $445.85 | 2019-2025 | |
| Amarin Pharma, INC. | $357.40 | 2020-2021 | |
| Amgen INC. | $349.01 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $339.65 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $292.49 | 2024-2025 | Rexulti |
| Lundbeck LLC | $284.25 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $208.52 | 2020-2025 | Mounjaro, Zepbound |
| Corium, LLC | $171.56 | 2022-2023 | Adlarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.71 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $114.27 | 2023 | Xarelto |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.